Makaro A, Kasprzak Z, Jaczynska M, Swierczynski M, Salaga M
Dig Dis Sci. 2025; .
PMID: 39971825
DOI: 10.1007/s10620-025-08873-8.
Zuo D, Lv L, Ren H, Sun H
Food Sci Nutr. 2024; 12(10):7306-7315.
PMID: 39479673
PMC: 11521629.
DOI: 10.1002/fsn3.4319.
Li S, Wang B, Zhang M, Yin Q, Yang Z, Li X
Front Pharmacol. 2024; 15:1460948.
PMID: 39444610
PMC: 11496122.
DOI: 10.3389/fphar.2024.1460948.
Bowe A, Kerr P
Adv Neurobiol. 2024; 35:287-313.
PMID: 38874729
DOI: 10.1007/978-3-031-45493-6_15.
Colon Ortiz R, Knerler S, Fridman L, Mercado A, Price A, Rosado-Franco J
Fluids Barriers CNS. 2024; 21(1):5.
PMID: 38200564
PMC: 10777548.
DOI: 10.1186/s12987-023-00507-3.
Translating Kratom-Drug Interactions: From Bedside to Bench and Back.
Tanna R, Cech N, Oberlies N, Rettie A, Thummel K, Paine M
Drug Metab Dispos. 2023; 51(8):923-935.
PMID: 37286363
PMC: 10353077.
DOI: 10.1124/dmd.122.001005.
Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom.
Tanna R, Nguyen J, Hadi D, Layton M, White J, Cech N
Clin Pharmacol Ther. 2023; 113(6):1315-1325.
PMID: 36924284
PMC: 10198846.
DOI: 10.1002/cpt.2891.
Computational Tools to Expedite the Identification of Potential PXR Modulators in Complex Natural Product Mixtures: A Case Study with Five Closely Related Licorice Species.
Alhusban M, Pandey P, Ahn J, Avula B, Haider S, Avonto C
ACS Omega. 2022; 7(30):26824-26843.
PMID: 35936409
PMC: 9352242.
DOI: 10.1021/acsomega.2c03240.
Potential Pharmacokinetic Effect of Chicken Xenobiotic Receptor Activator on Sulfadiazine: Involvement of P-glycoprotein Induction.
Li M, Xu Z, Lu W, Wang L, Zhang Y
Antibiotics (Basel). 2022; 11(8).
PMID: 35892397
PMC: 9394248.
DOI: 10.3390/antibiotics11081005.
The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma.
Liu X, Shang J, Fu Q, Lu L, Deng J, Tang Y
Front Oncol. 2022; 12:919027.
PMID: 35847963
PMC: 9281498.
DOI: 10.3389/fonc.2022.919027.
Evaluation of Potential Herb-Drug Interactions Between Shengmai Injection and Losartan Potassium in Rat and .
Niu Z, Qiang T, Lin W, Li Y, Wang K, Wang D
Front Pharmacol. 2022; 13:878526.
PMID: 35517807
PMC: 9065348.
DOI: 10.3389/fphar.2022.878526.
Antioxidant, Anticancer, and PXR-Dependent CYPA Attributes of (Burm.f.) Boiss., DC. and Boiss.
Shahbaz A, Iqbal J, Abbasi B, Akhtar W, Fatima I, Zahra S
Oxid Med Cell Longev. 2022; 2022:9366223.
PMID: 35222807
PMC: 8865984.
DOI: 10.1155/2022/9366223.
Herb-drug Interactions in Neuropsychiatric Pharmacotherapy - A Review of Clinically Relevant Findings.
Le T, McGrath S, Fasinu P
Curr Neuropharmacol. 2021; 20(9):1736-1751.
PMID: 34370637
PMC: 9881059.
DOI: 10.2174/1570159X19666210809100357.
Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.
Kou W, Sodhi J, Wu X, Benet L
Pharm Res. 2021; 38(5):795-801.
PMID: 33847849
PMC: 8501891.
DOI: 10.1007/s11095-021-03039-3.
Vinblastine treatment decreases the undifferentiated cell contamination of human iPSC-derived intestinal epithelial-like cells.
Ichikawa M, Negoro R, Kawai K, Yamashita T, Takayama K, Mizuguchi H
Mol Ther Methods Clin Dev. 2021; 20:463-472.
PMID: 33614822
PMC: 7868938.
DOI: 10.1016/j.omtm.2021.01.005.
Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.
Kwon Y, Shin S, Chun Y
Arch Pharm Res. 2021; 44(1):63-83.
PMID: 33484438
DOI: 10.1007/s12272-021-01306-w.
Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review.
Schimmel J, Dart R
Drugs. 2020; 80(3):263-283.
PMID: 31919755
DOI: 10.1007/s40265-019-01242-6.
Rapid maturation of the hepatic cell line Huh7 via CDK inhibition for PXR dependent CYP450 metabolism and induction.
Bulutoglu B, Mert S, Rey-Bedon C, Deng S, Yarmush M, Usta O
Sci Rep. 2019; 9(1):15848.
PMID: 31676845
PMC: 6825149.
DOI: 10.1038/s41598-019-52174-w.
7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects.
Kruegel A, Uprety R, Grinnell S, Langreck C, Pekarskaya E, Le Rouzic V
ACS Cent Sci. 2019; 5(6):992-1001.
PMID: 31263758
PMC: 6598159.
DOI: 10.1021/acscentsci.9b00141.
Kratom policy: The challenge of balancing therapeutic potential with public safety.
Prozialeck W, Avery B, Boyer E, Grundmann O, Henningfield J, Kruegel A
Int J Drug Policy. 2019; 70:70-77.
PMID: 31103778
PMC: 7881941.
DOI: 10.1016/j.drugpo.2019.05.003.